Literature DB >> 3125739

The cost of surveillance for adenocarcinoma complicating Barrett's esophagus.

E Achkar1, W Carey.   

Abstract

A review of endoscopic records at the Cleveland Clinic Foundation over a 7-yr period yielded 72 cases of Barrett's esophagus. Ten patients had adenocarcinoma at the time of diagnosis of Barrett's esophagus (14%). Sixty-two were followed for a mean of 31 months (range 2-154 months). During this follow-up period, cancer developed in one patient, an incidence of one cancer per 166 patient yr and an annual incidence of 0.6%. Males predominated in the group with both Barrett's esophagus (55 of 72) and adenocarcinoma (10 of 11). Symptoms were similar in those with simple Barrett's esophagus and those complicated by cancer. Our findings on incidence of cancer in Barrett's was applied to a model surveillance program. The cost of yearly endoscopic surveillance is estimated to be +62,000 and 78 lost work days to discover one cancer during the follow-up period. An endoscopic surveillance program requiring every-other-year studies appears justified and would cost only half as much, annually.

Entities:  

Mesh:

Year:  1988        PMID: 3125739

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  23 in total

1.  Surveillance in Barrett's esophagus: an audit of practice.

Authors:  Adewale Ajumobi; Khaled Bahjri; Christian Jackson; Ronald Griffin
Journal:  Dig Dis Sci       Date:  2009-08-11       Impact factor: 3.199

2.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus.

Authors:  M Miros; P Kerlin; N Walker
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 3.  Barrett's esophagus and esophageal adenocarcinoma: the scope of the problem.

Authors:  M S Levine; J B Herman; E E Furth
Journal:  Abdom Imaging       Date:  1995 Jul-Aug

Review 4.  Natural history of Barrett's esophagus.

Authors:  Rao Milind; Stephen E Attwood
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

Review 5.  Clinical implications of molecular changes in pediatric Barrett's esophagus.

Authors:  Licia Pensabene; Marta C Cohen; Michael Thomson
Journal:  Curr Gastroenterol Rep       Date:  2012-06

Review 6.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

7.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors:  P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

8.  Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Authors:  M Solaymani-Dodaran; R F A Logan; J West; T Card; C Coupland
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 9.  Role of surveillance in intestinal metaplasia of the esophagus and gastroesophageal junction.

Authors:  Guido N J Tytgat; Johanna W Van Sandick; J Jan B van Lanschot; Huug Obertop
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

Review 10.  Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management.

Authors:  H J Stein; J R Siewert
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.